<DOC>
	<DOCNO>NCT02913430</DOCNO>
	<brief_summary>To study progression free survival treatment Fulvestrant compare treatment tamoxifen Metastatic Breast Cancer .</brief_summary>
	<brief_title>Phase II Treatment Metastatic Breast Cancer With Fulvestrant Tamoxifen</brief_title>
	<detailed_description>The primary objective compare progression-free survival ( PFS ) fulvestrant tamoxifen arm patient unselected ESR1 mutation , subset patient ESR1-mt tumor assess primarily ctDNA enrollment . Patients ER+ breast cancer 1 3 prior line endocrine therapy one line chemotherapy MBC , exclude fulvestrant tamoxifen , randomize 1:1 ratio receive fulvestrant 500mg IM Q28 day one extra dose D15 first cycle ( load dose ) tamoxifen 20mg PO daily .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Signed informed consent 2 . Patients must histologically cytologically confirm invasive breast cancer ER+ ( &gt; 1 % stain ) radiographical clinical evidence metastatic disease a. Measurable and/or nonmeasurable disease 3 . Prior therapy : 1 . Patients must previously receive aromatase inhibitor adjuvant , neoadjuvant metastatic setting . 2 . The minimum duration AI adjuvant set 2 year . 3 . There minimum duration AI metastatic setting neoadjuvant setting . 4 . Patients may previously treat CDK 4/6 inhibitor mTOR inhibitor investigational agent addition aromatase inhibitor . 5 . Prior treatment tamoxifen allow adjuvant setting provide follow minimum 2 year AI . 4 . Brain metastasis allow previously treat , stable steroid minimum 56 day 5 . Age &gt; 18 year 6 . Male female breast cancer allowable 7 . Patients may pre postmenopausal ; premenopausal patient must ovarian suppression must adequately suppressed LHRH agonist estradiol level postmenopausal range a. Premenopausal patient pregnant must agree adequate birth control addition ovarian suppression . Agreement patient and/or partner use highly effective , nonhormonal form contraception two effective form nonhormonal contraception . Contraception use continue duration study treatment least 6 month last dose study treatment . 8 . ECOG performance status 02 9 . Adequate bone marrow function indicate follow , within 14 day enrollment : 1 . ANC ≥ 1500 cells/mm3 2 . Platelets ≥ 100,000 cells/ mm3 3 . Hemoglobin ≥ 9 g/dL 10 . Adequate liver function , indicate following , within 14 day enrollment . 1 . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) 2 . AST ≤ 1.5 x ULN 3 . ALT ≤ 2.5 x ULN 4 . Alkaline phosphatase ≤ 2.5 x ULN follow exception ; ALP ≤ 5× ULN patient bone metastasis . 11 . Adequate hemostatic function determine PT , INR aPTT &lt; 1.5× ULN ( unless therapeutic coagulation , case adequate level anticoagulation determine investigator ) . 12 . Adequate renal function , indicate creatinine ≤ 1.5 x ULN . 1 . Prior therapy exclusion : 1 . Prior therapy fulvestrant 2 . Prior therapy tamoxifen metastatic set 3 . More 3 prior line endocrine therapy metastatic set 4 . More one prior line chemotherapy metastatic set 2 . Washout 2 week require aromatase inhibitor ; washout 4 week require CDK 4/6 inhibitor , everolimus biological agent . 3 . Patients must receive investigational agent . 4 . Patients symptomatic , untreated CNS metastasis eligible . 5 . Patients may significant concurrent illness , infection , pregnancy lactation 6 . Patients must different active malignancy , except skin basal cell carcinoma , skin squamous cell carcinoma cervical intraepithelial neoplasia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>